ESSA Pharma Inc. (EPIX) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

ESSA Pharma Inc. (EPIX)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

1.76

-0.01 (-0.56%)

At close: Jan 15, 2025, 3:59 PM

1.76

-0.28%

After-hours Jan 15, 2025, 04:00 PM EST

undefined% (undefined)

Bid	1.75
Market Cap	78.31M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-0.64
PE Ratio (ttm)	-2.76
Forward PE	n/a
Analyst	Hold

Ask	1.81
Volume	95,175
Avg. Volume (20D)	1,033,459
Open	1.78
Previous Close	1.77
Day's Range	1.76 - 1.82
52-Week Range	1.40 - 11.67
Beta	undefined

About EPIX

ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. It develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer. The company has collaboration agreements with Caris Life Sciences, Inc.; Bayer Consumer Care AG; Janssen Research & Development, LLC; and A...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Mar 13, 2015

Employees 50

Stock Exchange NASDAQ

Ticker Symbol EPIX

Website https://www.essapharma.com

Analyst Forecast

According to 3 analyst ratings, the average rating for EPIX stock is "Hold." The 12-month stock price forecast is $2, which is an increase of 13.31% from the latest price.

Buy 0.00%

Hold 100.00%

Sell 0.00%

Stock Forecasts

Why Price Moved

2 months ago · Source

-73.08%

ESSA Pharma shares are trading lower after the com... Unlock content with Pro Subscription

4 months ago · Source

+2.19%

ESSA Pharma shares are trading higher after the company announced it presented data on prostate cancer therapy Masofaniten at ESMO 2024.

News

7 months ago · seekingalpha.com

ESSA Pharma's Speculative Buy Potential: Masofaniten Promise For Prostate Cancer

ESSA Pharma Inc. is developing Masofaniten, a drug that disrupts the androgen receptor to stop prostate cancer growth, with promising results in phase 1 trials. Masofaniten has the potential to overco...